Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Crohn'S & Colitis|September 21, 2021
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's DiseaseWilliam J Sandborn, James D Lewis, Julian Panes, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trialDésirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateMark C Genovese, Josef S Smolen, Michael E Weinblatt, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 10, 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled TrialRoy Fleischmann, Aileen L Pangan, In-Ho Song, et al.
Rheumatology (Oxford, England)|December 27, 2014
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumabDésirée van der Heijde, Maxime Breban, Dale Halter, et al.
Lancet (London, England)|May 28, 2019
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 studyJosef S Smolen, Aileen L Pangan, Paul Emery, et al.
RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.
The New England Journal of Medicine|March 31, 2021
Trial of Upadacitinib and Adalimumab for Psoriatic ArthritisIain B McInnes, Jaclyn K Anderson, Marina Magrey, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Pageof 5